The current paradigm for biologic initiation: a confirmatory quantitative analysis of self-injection training practices.

Self-injection biologic initiation combination product drug delivery device injection anxiety injection training patient support training device

Journal

Expert opinion on drug delivery
ISSN: 1744-7593
Titre abrégé: Expert Opin Drug Deliv
Pays: England
ID NLM: 101228421

Informations de publication

Date de publication:
06 2022
Historique:
pubmed: 19 5 2022
medline: 12 7 2022
entrez: 18 5 2022
Statut: ppublish

Résumé

Self-injected biologic therapies have gained significant prevalence across numerous therapeutic areas. A lack of specific guidance on best practices may lead to inadequate biologic initiation and training. We previously conducted a small-sample, qualitative analysis designed to identify gaps in self-injection training. A total of 277 HCPs performing routine biologic initiation and 264 patients currently self-injecting biologics completed this quantitative study remotely using an online survey. The primary objective was to validate previous qualitative findings and firmly characterize the current paradigm. As an exploratory objective, the study examined associations that may exist between training experiences and patient-reported outcomes. Most patients (91.7%) reported receiving formal self-injection training, commonly conducted over one or two sessions. The mean overall training time reported was 37.8 and 30.4 minutes by patients and HCPs, respectively. Over one-third of patients reported lacking confidence that they could correctly self-inject during the first 6 months of treatment. Current training practices may not be adequate to prepare patients to start their therapies. Considerable attention must be paid to providing patients with multiple opportunities for training sessions, training devices, and medical information for home access. Further studies should prospectively examine the impact of training techniques on patient-reported outcomes.

Sections du résumé

BACKGROUND
Self-injected biologic therapies have gained significant prevalence across numerous therapeutic areas. A lack of specific guidance on best practices may lead to inadequate biologic initiation and training. We previously conducted a small-sample, qualitative analysis designed to identify gaps in self-injection training.
METHODS
A total of 277 HCPs performing routine biologic initiation and 264 patients currently self-injecting biologics completed this quantitative study remotely using an online survey. The primary objective was to validate previous qualitative findings and firmly characterize the current paradigm. As an exploratory objective, the study examined associations that may exist between training experiences and patient-reported outcomes.
RESULTS
Most patients (91.7%) reported receiving formal self-injection training, commonly conducted over one or two sessions. The mean overall training time reported was 37.8 and 30.4 minutes by patients and HCPs, respectively. Over one-third of patients reported lacking confidence that they could correctly self-inject during the first 6 months of treatment.
CONCLUSION
Current training practices may not be adequate to prepare patients to start their therapies. Considerable attention must be paid to providing patients with multiple opportunities for training sessions, training devices, and medical information for home access. Further studies should prospectively examine the impact of training techniques on patient-reported outcomes.

Identifiants

pubmed: 35582857
doi: 10.1080/17425247.2022.2078300
doi:

Substances chimiques

Biological Products 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

733-742

Auteurs

James Hawthorne (J)

Matchstick LLC, Boonton, NJUSA.
Department of Pharmacy, University of Rhode Island, Kingston, RI.

Dimos Katsaros (D)

Matchstick LLC, Boonton, NJUSA.
Department of Pharmacy, University of Rhode Island, Kingston, RI.

Amy Rinaldi (A)

Matchstick LLC, Boonton, NJUSA.

Katherine Brigham (K)

Matchstick LLC, Boonton, NJUSA.

Matthew D'Auria (M)

Matchstick LLC, Boonton, NJUSA.

Erika Bajars (E)

Matchstick LLC, Boonton, NJUSA.

Chris Franzese (C)

Matchstick LLC, Boonton, NJUSA.
Department of Pharmacy, University of Rhode Island, Kingston, RI.

Marty Coyne (M)

Matchstick LLC, Boonton, NJUSA.
Department of Pharmacy, University of Rhode Island, Kingston, RI.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH